Foley Hoag LLP represented Ginkgo Bioworks (NYSE: DNA) ("Ginkgo"), the leading platform for cell programming and biosecurity, in a new collaboration agreement with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug candidates.
In the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas. Ginkgo will receive an upfront payment and is eligible to receive research fees and development and commercial milestone payments, up to an aggregate total of $331 million across three programs. Ginkgo is entitled to potential further downstream value in the form of royalties on sales.
Foley Hoag attorneys Sarah Cooleybeck and Ivanna Bihun represented Ginkgo in the transaction, with assistance from John Harre, Mark Potash, Anna Cardoso, Alison Bauer, Nicola Lemay, and Christopher Escobedo Hart.